SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (325)12/8/2005 7:34:16 PM
From: Miljenko Zuanic  Read Replies (1) of 447
 
<<What will be the incentive for docs to fool around with an unapproved and potentially risky use of Avastin when there is no evidence that Avastin will work any better than Lucentis?>>

MDs incentive is more frequent injections and pts visit to office, and this favor Lucentis vs Avastin. For now DNA may charge for Lucentis as much as they want, but down the road there will be competition drug(s), and Avastin economic will be important. Unless US public continue to express stupidity, as they usually do.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News